1
|
Li J, Yu H, Wang X, Ye Y, Fang W, Ding N, Mi L, Ping L, Wang X, Song Y, Zhu J. The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma. Cancer Control 2022; 29:10732748221143881. [PMID: 36519740 PMCID: PMC9761230 DOI: 10.1177/10732748221143881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
INTRODUCTION Mantle cell lymphoma (MCL) is an aggressive and incurable B-cell-derived malignant disease. MCL is treated using general chemotherapy; however, disease progression and relapse are common; thus, the development of novel therapeutic targets for treatment of MCL is urgently required. Serum- and glucocorticoid-inducible kinase 1 (SGK1) is involved in various cellular activities, and its dysregulation contributes to the pathogenesis of multiple types of cancer. However, little is known regarding its functional roles and associated molecular mechanisms in MCL. METHODS SGK1 inhibition mediated by either shRNA or treatment with SGK1 inhibitor (GSK650394) was conducted in MCL cell lines. Western blotting analysis was performed to figure out the expression of related proteins. MCL-cell-derived xenograft models were constructed to evaluate the anti-tumor effects of SGK1 inhibition or/and Bruton's tyrosine kinase (BTK) inhibition in vivo. RESULTS In this study, it was shown that inhibition of SGK1 significantly reduced cell proliferation, invasion and migration, increased apoptosis and blocked cell cycle progression in MCL cells. Furthermore, SGK1 inhibition significantly reduced the activation of ERK, AKT/mTOR, JAK2/STAT3 and the NF-κB signaling pathways. Using MCL-cell-derived xenograft mice models, SGK1 inhibition decreased tumor cell proliferation and tumor growth. Importantly, SGK1 overexpression significantly promoted xenograft tumor growth. Moreover, simultaneous inhibition of SGK1 and Bruton tyrosine kinase (BTK) resulted in synergistic anti-tumor effects on MCL both in vitro and in vivo. CONCLUSION SGK1 may be a novel candidate therapeutic target and simultaneous inhibition of SGK1 and BTK may be a promising therapeutic strategy for MCL patients. Further pre-clinical and even clinical studies of SGK1 inhibitor or combination with BTK inhibitor are essential.
Collapse
Affiliation(s)
- Jiao Li
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Hui Yu
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Xing Wang
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Yingying Ye
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Wei Fang
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Ning Ding
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Lan Mi
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Lingyan Ping
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Xiaogan Wang
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Yuqin Song
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China
| | - Jun Zhu
- Key Laboratory of Carcinogenesis
and Translational Research (Ministry of Education), Department of lymphoma,
Peking
University Cancer Hospital, Institute,
Beijing, China,Jun Zhu and Yuqin Song, Key Laboratory of
Carcinogenesis and Translational Research (Ministry of Education), Department of
Lymphoma, Peking University Cancer Hospital & Institute, 52 Fucheng Road,
Haidian, Beijing 100142, China. ;
| |
Collapse
|
2
|
Luong TTD, Tuffaha R, Schuchardt M, Moser B, Schelski N, Boehme B, Gollmann-Tepeköylü C, Schramm C, Holfeld J, Pieske B, Gulbins E, Tölle M, van der Giet M, Lang F, Eckardt KU, Voelkl J, Alesutan I. Acid sphingomyelinase promotes SGK1-dependent vascular calcification. Clin Sci (Lond) 2021; 135:515-34. [PMID: 33479769 DOI: 10.1042/CS20201122] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 01/07/2021] [Accepted: 01/21/2021] [Indexed: 12/20/2022]
Abstract
In chronic kidney disease (CKD), hyperphosphatemia is a key factor promoting medial vascular calcification, a common complication associated with cardiovascular events and high mortality. Vascular calcification involves osteo-/chondrogenic transdifferentiation of vascular smooth muscle cells (VSMCs), but the complex signaling events inducing pro-calcific pathways are incompletely understood. The present study investigated the role of acid sphingomyelinase (ASM)/ceramide as regulator of VSMC calcification. In vitro, both, bacterial sphingomyelinase and phosphate increased ceramide levels in VSMCs. Bacterial sphingomyelinase as well as ceramide supplementation stimulated osteo-/chondrogenic transdifferentiation during control and high phosphate conditions and augmented phosphate-induced calcification of VSMCs. Silencing of serum- and glucocorticoid-inducible kinase 1 (SGK1) blunted the pro-calcific effects of bacterial sphingomyelinase or ceramide. Asm deficiency blunted vascular calcification in a cholecalciferol-overload mouse model and ex vivo isolated-perfused arteries. In addition, Asm deficiency suppressed phosphate-induced osteo-/chondrogenic signaling and calcification of cultured VSMCs. Treatment with the functional ASM inhibitors amitriptyline or fendiline strongly blunted pro-calcific signaling pathways in vitro and in vivo. In conclusion, ASM/ceramide is a critical upstream regulator of vascular calcification, at least partly, through SGK1-dependent signaling. Thus, ASM inhibition by repurposing functional ASM inhibitors to reduce the progression of vascular calcification during CKD warrants further study.
Collapse
|
3
|
Zhang M, Chen H, Liu MS, Zhu KY, Hao Y, Zhu DL, Li P. Serum- and glucocorticoid-inducible kinase 1 promotes insulin resistance in adipocytes via degradation of insulin receptor substrate 1. Diabetes Metab Res Rev 2021; 37:e3451. [PMID: 33724645 DOI: 10.1002/dmrr.3451] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 01/08/2021] [Accepted: 02/24/2021] [Indexed: 11/11/2022]
Abstract
AIMS Accumulating evidence indicates that serum- and glucocorticoid-inducible kinase 1 (SGK1) plays a role in the development of metabolic syndrome via a poorly understood mechanism. This study aimed to investigate the direct effect of SGK1 on insulin sensitivity in adipose tissue. MATERIALS AND METHODS We ectopically expressed or silenced SGK1 in adipocytes via lentiviral transfection, measured glucose uptake and evaluated insulin signalling using western blotting. In vivo insulin resistance was measured at the whole-body and adipose tissue levels in db/db mice treated with an inhibitor of SGK1. RESULTS After 8 weeks of SGK1 inhibitor treatment, the serum insulin level and homeostasis model assessment of insulin resistance index were significantly decreased, and AKT phosphorylation in adipose tissue was enhanced in db/db mice. Overexpression of constitutively active SGK1 in adipocytes in vitro decreased AKT phosphorylation and insulin-stimulated glucose uptake. Dexamethasone and oleic acid increased SGK1 expression and decreased AKT phosphorylation and insulin receptor substrate expression in adipocytes. Administration of an inhibitor of SGK1 or Lv-shSGK1 reversed the suppression of insulin signalling induced by dexamethasone and oleic acid. SGK1 overexpression increased FoxO1 phosphorylation, and administration of Lv-shSGK1 reversed an increase in FoxO1 phosphorylation induced by dexamethasone and oleic acid. CONCLUSIONS Thus, SGK1 mediates the effect of glucocorticoids and high-fat feeding and induces insulin resistance in adipocytes. Our data suggest that SGK1 is a possible therapeutic target for metabolic syndrome and related complications.
Collapse
Affiliation(s)
- Min Zhang
- Department of Endocrinology, Taikang Xianlin Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, People's Republic of China
| | - Huan Chen
- Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, People's Republic of China
| | - Meng-Si Liu
- Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, People's Republic of China
| | - Ke-Ying Zhu
- Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, People's Republic of China
| | - Yan Hao
- Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, People's Republic of China
| | - Da-Long Zhu
- Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, People's Republic of China
| | - Ping Li
- Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, People's Republic of China
| |
Collapse
|